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Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with widespread occurrence and diverse func-
tions. PACAP binds to specific PAC1 and non-specific VPAC1/2 receptors. PACAP is considered as a growth factor, as it 
plays important roles during development and participates in reparative processes. Highest concentrations are found in the 
nervous system and endocrine glands, where several functions are known, including actions in tissue growth, differentia-
tion and tumour development. Therefore, we have investigated expression of PACAP and its receptors in different tumours, 
including those of endocrine glands. We showed earlier that PACAP and PAC1 receptor staining intensity decreased in 
pancreatic ductal adenocarcinoma. In the present study we aimed to investigate alterations of PACAP and PAC1 receptor in 
human insulinoma and compared the immunostaining pattern with samples from chronic pancreatitis patients. We collected 
perioperative and histological data of patients who underwent operation because of insulinoma or chronic pancreatitis over 
a five-year-long period. Histology showed chronic pancreatitis with severe scar formation in pancreatitis patients, while 
tumour samples evidenced Grade 1 or 2 insulinoma. PACAP and PAC1 receptor expression was studied using immunohis-
tochemistry. Staining intensity was very strong in the Langerhans islets of normal tissue and discernible staining was also 
observed in the exocrine pancreas. Immunostaining intensity for both PACAP and PAC1 receptor was markedly weaker in 
insulinoma samples, and disappeared from chronic pancreatitis samples except for intact islets. These findings show that 
PAC1 receptor/PACAP signalling is altered in insulinoma and this suggests a possible involvement of this system in tumour 
growth or differentiation.
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Introduction
Both benign and malignant pancreas diseases are frequent. 
Adenocarcinoma of the pancreas is among the most malig-
nant tumours, while acute and chronic pancreatitis affect 
a large population all around the world. Insulinoma is a 
benign, rare tumour type, many times with complicated 
diagnosis and therapy. Chronic pancreatitis is associ-
ated with repeated inflammations, causing tissue fibrosis, 
often pain and destruction of the pancreas. It affects both 
the endocrine and the exocrine parts of the organ, with 
need for specific nutrition and diet (Gress et al. 1994a, b; 
Michalski et al. 2008; Wiese et al. 2020). Epidemiological 
data are difficult to estimate (incidence is varying from 
4 to 13.4/100.000), because patients have often compli-
ance problems as chronic alcoholism is one of the leading 
causes of this disease (Lévy et al. 2014). It is known that 
patients with chronic pancreatitis have 13.3 times higher 
risk for pancreas malignancy than healthy people (Rai-
mondi et al. 2010). Some symptoms of chronic pancrea-
titis and pancreas carcinoma are similar and because of 
the non-specific symptoms correct diagnosis and definite 
decision is difficult to make. Based on these facts, severe 
chronic pancreatitis and suspect tumour onset represent 
operative indication.
Insulinoma is a rare insulin-producing neuroendocrine 
tumour. It is the most common cause of hypoglycaemia 
associated with endogenous high level of insulin, in some 
cases associated with MEN-1 (multiple endocrine neopla-
sia) syndrome (Shin et al. 2010). The obligatory diagnos-
tic triad (Whipple’s triad) for insulinoma are fasting pro-
voked hypoglycaemia, blood glucose level under 50 mg/dl 
at the onset of symptoms, and the decrease of symptoms 
after glucose administration (Whipple and Frantz 1935). 
The incidence of insulinoma is generally about 0.4% and 
1–4/1,000,000 of the population is affected (Mehrabi et al. 
2014; Shin et al. 2010). Most insulinomas are benign, sol-
itary, and surgical resection ensure complete resolution 
of the illness. Enucleation is the appropriate solution in 
most cases, but rarely, such as in case of malignant insu-
linoma, pancreas resection or cytoreductive surgery is also 
recommended. Simultaneous oncotherapy is frequently 
needed in these severe cases. In the 1950′s administra-
tion of diazoxide was widely used. This antihypertensive 
agent, used orally, inhibits insulin release from the β-cells 
by α-adrenergic receptor stimulation. Mild and tolerable 
side effects, such as fluid retention, nausea, hirsutism, 
made the use of this drug complicated (Gill et al. 1997; 
Goode et al. 1986). New approach shows the use of long-
acting somatostatin analogues (octreotide), which decrease 
plasma insulin concentration (Maton 1993). Octreotide can 
produce side effects similar to those in somatostatinoma: 
diabetes, cholelithiasis, weight loss. The goal of the drug 
administration in advanced cases is to lengthen time until 
surgery or patient palliation in incurable cases (Burns and 
Edil 2012; Okabayashi et al. 2013; Shin et al. 2010).
Pituitary adenylate cyclase activating polypeptide 
(PACAP) is a 27- or 38-amino acid neuropeptide, first iso-
lated as a hypothalamic neuropeptide acting on the pitui-
tary cAMP release (Hirabayashi et al. 2018; Miyata et al. 
1989). PACAP has two forms: one has 38 amino acid resi-
dues (PACAP38), while the shorter form has 27 amino acids 
(PACAP27) (Miyata et al. 1990). Several former studies 
proved that PACAP can be found in the entire body, with 
the highest concentrations in the central nervous system 
and endocrine glands, but it is also present in the digestive, 
cardiovascular, and urogenital systems (Elsas et al. 1996; 
Lajko et al. 2018; Ojala et al. 2019; Parsons and May 2019; 
Reglodi et al. 2018; Sarszegi et al. 2019; Reglodi and Tamas 
2016; Vaudry et al. 2009). The neuropeptide has diverse 
functions by binding to specific PAC1, and non-specific 
VPAC1 and VPAC2 receptors. Among others, the effects 
of PACAP have been shown in the Schwann cells, retina, 
cornea, smooth muscle contractility, neuronal excitability 
and fertility (Maugeri et al. 2019a; b, c; May et al. 2021; 
Shan et al. 2021). The VPAC receptors bind the homolo-
gous VIP peptide (vasoactive intestinal peptide) with equal 
affinity, while PAC1 is specific for PACAP (Girard et al. 
2020; Reglodi et al. 2018; Rytel et al. 2020; Vaudry et al. 
2009). PACAP and PACAP receptors have been detected in 
various exocrine glands: there are numerous PACAP-ergic 
fibers in the lacrimal gland (Elsas et al. 1996) and PAC1 
receptors are involved in stimulation of tear secretion (Gaál 
et al. 2008; Nakamachi et al. 2016). PACAP-ergic nerves and 
PACAP receptors have also been described in the mammary 
and salivary glands (Czegledi et al. 2011; Pedersen et al. 
2000; Pohóczky et al. 2020; Skakkebaek et al. 1999; Tobin 
et al. 1995). In the salivary glands, PACAP stimulates secre-
tion (Matoba et al. 2016) and increases protein production 
(Calvert et al. 1998; Kamaishi et al. 2004; Mirfendereski 
et al. 1997). PACAP has also been described in the exocrine 
pancreas, which is analogous to a serous salivary gland in 
structure (Schmidt et al. 1993). The endocrine part of the 
pancreas, containing the islets of Langerhans, expresses 
markedly high levels of PACAP, similarly to other endocrine 
glands (Ferencz et al. 2019). The intrapancreatic PACAP has 
an important effect in the regulation of beta cell prolifera-
tion (Sakurai et al. 2011) and it plays an important regu-
latory role in both insulin and glucagon secretion. In vitro 
and in vivo studies have shown that PACAP increases insu-
lin outflow after glucose stimulation in mouse and human 
models. Both subtypes elevate insulin secretion on isolated 
islets and perfused pancreas, where the stimulating potential 
of PACAP27 and PACAP38 is equal (Fridolf et al. 1992; 
Klinteberg et al. 1996; Yada et al. 1994). It has been shown 
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that PACAP38 stimulates insulin secretion glucose- and 
dose-dependently via the PAC1 receptor, not by VPAC1 or 
VPAC2 receptors (Liu et al. 2019). It has also been proven 
that PAC1 and VPAC2 receptor deletion can cause glucose 
intolerance, influencing mediation of prandial insulin secre-
tion and glucagon response to hypoglycaemia (Winzell and 
Ahrén 2007).
Numerous studies have described changes of PACAP and 
PACAP receptors expression in pathological conditions, 
including pancreas diseases. In a mouse model of pancrea-
titis induced by cerulein, increased pancreatic expression of 
PACAP could be observed (Hamagami et al. 2009). PACAP, 
along with its receptors, is involved in cell proliferation and 
differentiation, as well as tumour transformation (Jung et al. 
2011; Moody et al. 2003, 2016; Moody and Jensen 2016; 
Schulz et al. 2004, 2015). PACAP can function as a growth 
factor for some tumour cells (Moody et al. 2003), while it 
inhibits growth of others (Wojcieszak and Zawilska 2014). 
PACAP increases tumour proliferation on AR4-2 J rat pan-
creatic carcinoma cell line (Schäfer et al. 1996). PACAP and 
PAC1 receptor expression can be altered in several types 
of tumours such as thyroid papillary carcinoma or testis 
cancer (Bardosi et al. 2016; Nakamura et al. 2014). Previ-
ous findings have shown messenger RNA of PAC1, VPAC1 
and VPAC2 in insulinoma cells (Borboni et al. 1999). It is 
also known that PACAP inhibits pancreas islet mass expan-
sion and pancreatic islet density, which is associated with 
islet neogenesis in type II diabetes (Inoue et al. 2013). In 
our recent study, we investigated histological samples from 
pancreas ductal adenocarcinoma patients. The staining 
intensity of PAC1 receptor was strong in normal tissues of 
pancreas, but it was much weaker in the adenocarcinoma. 
We found a very high level of immunostaining of PACAP in 
islets and nerves in tumour-free parts and very weak inten-
sity in the exocrine parts. In the carcinoma samples there 
was no PACAP immunostaining. We supposed that the lack 
of PAC1 receptor/PACAP signalling could have an impact 
on growth and differentiation of pancreas adenocarcinoma 
(Ferencz et al. 2019). However, it is not known how expres-
sion of PACAP and its specific receptor change in pancreas 
insulinoma. Therefore, the aim of the present study was to 
investigate whether there is a change in the expression of 
PACAP and PAC1 receptor in insulinoma and we used sam-
ples from chronic pancreatitis patients for comparison.
Materials and Methods
Data Collection of the Patients
A 5-year-long period (January 2014–August 2018) was 
investigated. Pre- and perioperative patient data were col-
lected. All patients were operated in our Department of 
Surgery because of either chronic pancreatitis, suspected 
pancreas tumour, or insulinoma proven with fine needle 
aspiration biopsy. Operation type, as well as histological 
findings, grading, and margin resection were investigated 
(ethical permission number: PTE/83069/2018).
Histology and Immunohistology
Following complete patient data collecting new histologi-
cal sections were made and prepared for further specific 
histological examination of PACAP and PAC1 receptor 
expression. Immunohistochemical staining was performed 
on 2-μm-thick paraffin sections fixed in 4% buffered forma-
lin. Sections were stained with human anti-PACAP38 anti-
body (Peninsula, CA, USA, dilution of 1:200) and human 
PAC1 receptor antibody raised in rabbit (Sigma-Aldrich, 
Budapest, Hungary, dilution of 1:200), following standard 
immunohistochemical procedures. Staining was performed 
with EnVision FLEX Visualization Systems for Dako Omins 
(Dako, Denmark), similarly to earlier descriptions (Ferencz 
et al. 2019; Nakamura et al. 2014). As a chromogen for the 
immunohistochemical staining, liquid fast-red substrate kit 
(Abcam, UK) was used. Pathological analysis was done by 
expert pathologists. By omitting the primary antiserum, a 
method control was performed, which resulted in no stain-
ing. Tumour cell staining intensity was compared to that of 




In chronic pancreatitis patients, the histological samples of 
thirty patients (23 males and 7 females, in the age of 30 to 
75 years; mean age 56,8 years) were collected. Frey opera-
tion was performed in twenty cases, pancreatoduodenectomy 
in five cases, and cystojejunostomy in the other five cases. 
Data of five patients with insulinoma (3 males, 2 females, 
in the age of 26 to 50 years; mean age 40,6 years) were 
investigated. Enucleation of insulinoma was performed in 
three patients, in case of 1 patient distal pancreas resection 
and splenectomy, by another patient conventional Whipple 
operation was chosen. Except for patients undergoing only 
enucleation, all other patients were transferred to the Inten-
sive Care Unit (ICU) for a routine postoperative observa-
tion. No complication appeared; all patients were emitted 
8–14 days after surgery.
The histological results showed advanced chronic pan-
creatitis with severe scar formation in all chronic pancreati-
tis patients, there was no sign for malignancy. Histological 
examination of insulinoma cases showed Grade 1 insulinoma 
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in four patients, and Grade 2 in one patient. Tumour stag-
ing in three cases was pT1, in two cases pT2. Lymph node 
staging was N0 in two cases (Whipple operation and distal 
pancreas resection), the other specimens (enucleation) con-
tained no lymph nodes. Resection margin was not affected 
(R0 resection) in three cases and samples from two patients 
showed affected resection margin (R1 resection), without 
perineural, perivascular invasion.
Histology and Immunohistology
In accordance with our earlier observations (Ferencz et al. 
2019), strong PACAP and PAC1 receptor immunohisto-
chemical staining was detected in the Langerhans islets of 
normal pancreatic tissue and discernible staining could be 
observed in the exocrine pancreas (Figs. 1, 2). Insulinoma 
cells showed positivity for both PACAP and PAC1 recep-
tor, however, the expression of PACAP and its receptor was 
markedly weaker than in normal islets (Fig. 2b).
In chronic pancreatitis the loss of exocrine structures with 
relative sparing of islets, fibrosis and signs of chronic inflam-
mation could be detected with preserved strong PACAP and 
PAC1 receptor staining in the islets and without PACAP 
or PAC1 receptor staining in the area of chronic inflamma-
tion (Fig. 3). Thus, our results show that PACAP and PAC1 
Fig. 1  PACAP immunostaining in normal pancreas and insulinomas. 
Scale bar: 100 µm (in insert 50 µm). Normal, strong PACAP staining 
was present in the healthy islets (arrow in a and insert picture of b). 
The normal exocrine part showed mild staining intensity (left side of 
a and b), while in case of the insulinoma cells (right side of a and b) 
a weak staining could be observed. In picture b the staining intensity 
of the insulinoma cells can be compared with a healthy islet (insert)
Fig. 2  PAC1 receptor immunostaining in normal pancreas and insu-
linomas. Scale bar: 200 µm. Normal, strong PAC1 receptor staining 
in the healthy islets (arrows in b) and mild staining intensity of the 
normal exocrine part (left side of a and b) could be detected. The 
tumour cells (right side of a and b) showed very weak staining
Fig. 3  PACAP (a) and PAC1 receptor (b) immunohistochemistry in 
chronic pancreatitis. Scale bar: 100 µm. Normal, strong PACAP and 
PAC1 receptor staining intensity could be observed in the islets. The 
exocrine part showed histological signs of chronic inflammation with-
out specific immunostaining pattern
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receptor-like immunoreactivity is strongly reduced in insu-
linomas compared to normal islets.
Discussion
In our study we analysed normal pancreas, chronic pancrea-
titis and insulinoma samples for PACAP and PAC1 recep-
tor immunostaining. We found a decreased or diminished 
peptide and receptor expression in the insulinoma parts 
compared to the normal tissue. This finding is similar to 
our earlier observation in pancreatic ductal adenocarcinoma, 
where we also found diminished expression of PACAP and 
PAC1 receptor in the adenocarcinoma parts compared to 
normal exocrine acini. Although these two tumours are 
completely different in development, malignancy and cell 
type, the expression pattern of the peptide and its receptor 
changed in a similar way.
PACAP is known to be involved in the growth and dif-
ferentiation of various tumour types. The participation of 
PACAP in tumour growth is varying depending on the cell 
type, differentiation stage of the tumour and PACAP con-
centration. Thus, while PACAP stimulates growth of some 
tumour cells due to its antiapoptotic actions, it inhibits pro-
liferation of other tumour cell types and was even found 
to inhibit migration of malignant cells (Moody et al. 2020; 
Toth et al. 2020). Several environmental circumstances also 
influence the exact effect of PACAP. For example, PACAP, 
by itself, had no effect on the proliferation or survival of JAR 
choriocarcinoma cells, but enhanced the cell death promot-
ing effect of oxidative stress (Boronkai et al. 2009). Less is 
known about the actions of PACAP in benign tumour cells 
and little is known about PACAP and its receptors also in 
endocrine tumours. As PACAP is very strongly expressed 
in endocrine glands, attention should be focused on endo-
crine tumours. Some data are available, but this field lacks 
systematic investigation. For example, PACAP has been 
shown to induce vascular endothelial growth factor produc-
tion and activate voltage-gated sodium channels in pituitary 
adenoma (Koshimura et al. 1997; Lohrer et al. 2001), but 
it inhibits apoptosis in another human pituitary adenoma 
cell line (Oka et al. 1999). PACAP is found in the major-
ity of human pheochromocytoma cases, and these cells are 
also often used in studying mechanisms of PACAP (Inoue 
et al. 2020; Thouënnon et al. 2010). Altered PACAP and 
PAC1 receptor expression has also been described in thyroid 
tumours (Bardosi et al. 2016).
Our findings in insulinomas are in contrast to what we 
had expected. Both PACAP and its closely related pep-
tide, VIP, are strongly expressed in the endocrine cells of 
the insula, we expected that a cell proliferation from these 
cells would also show strong expression. Other studies in 
VIPomas strengthened this hypothesis, as strong VIP and 
VPAC receptor expression was described in a VIPoma case 
(Nakayama et al. 2009). Similar to our present findings, a 
decrease in immunosignal for PACAP was also observed in 
parathyroid adenomas (Luts et al. 1996).
It is well known that numerous growth factors play an 
important role in pancreatic organogenesis and are con-
nected with some pathological disorders. The pro-inflam-
matory cytokines interleukin-1-beta and interferon-gamma 
elevate mitochondrial superoxide levels leading to beta cell 
failure and loss of insulin-producing cells in vitro (Barlow 
et al. 2018). Fibroblast growth factor (FGF) is involved in 
regulation of tumour growth and differentiation, but on the 
other hand FGF is also known to refine insulin sensitivity in 
obese animal models (Xu et al. 2017). Transforming growth 
factor beta’s important role in tumour growth is well docu-
mented and it also stimulates pancreatic islet cells (Sayo 
et al. 2000). Previous studies showed that high expression 
of nerve growth factor (NGF) in the pancreas is associated 
with increased inflammatory response and more severe pain 
(Saloman et al. 2018). Studies showed that both the insu-
lin and NGF immunofluorescent labelling was weaker in 
insulinoma samples (Vidaltamayo et al. 2003). Epidermal 
growth factor (EGF) appears in pancreatic ductal adenocar-
cinomas, and an in vitro study showed increase in level of 
JNK after administration of EGF, vitronectin and fibronectin 
in insulinoma cells (Kacar and Bolkent 2019).
The diagnosis and follow-up of prognosis is difficult in 
cases of variable malignancies, as well as neuroendocrine 
tumours, the available biomarkers at present have mild 
sensitivity and specificity. Nowadays precise, personalized 
treatment approaches, reliable prognostic, and treatment 
-predictive biomarkers are needed (Le et al. 2016; Loosen 
et al. 2017; Yamaoka et al. 2017). Although neuroendo-
crine tumours of the pancreas are rare malignancies, most 
of them are part of hereditary syndromes, with increased 
need for good diagnostic markers. In cases of pancreatic 
neuroendocrine tumours (PNETs) Chromogranin A (Cg 
A) seems to be a reliable serum diagnostic marker, but it 
is proven that Cg A is not sensitive and specific enough 
in insulinoma patients (Qiao et al. 2014). There is a trend 
for combination of biomarkers (e.g. neurone specific eno-
lase, pancreatic polypeptide) with Cg A (Bocchini et al. 
2020; Chen et al. 2019). The neuropeptide PACAP has an 
important role in the development of nervous system and 
of peripheral organs (Fulop et al. 2019; Sandor et al. 2016; 
Xu et al. 2016). Based on this fact, it is not suprising that 
some of the tumours can express alterations in PACAP and/
or receptors. Some tumour types show overexpression, while 
others show decrease in PACAP-ergic signalling. In vitro 
studies proved the stimulating or inhibiting effect of PACAP 
on tumour growth, depending on some factors like tumour 
type, differentiation level, origin of the tumour or its envi-
ronment (Zibara et al. 2018). For example, PACAP can 
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decrease cell survival on retinoblastoma cells (Wojcieszak 
and Zawilska 2014), leads to milder invasive ability of glio-
blastoma cells (Maugeri et al. 2016), induces neuroblas-
toma differentiation into benign form (Maugeri et al. 2018) 
and inhibits tumour growth in cervix carcinoma (Lee et al. 
2014). In contrast, PACAP can induce proliferation of an 
osteosarcoma cell line (Juhász et al. 2014) and the number 
of viable cells increases in some colon tumour cell lines 
(Le et al. 2002). Alternating effects can even be observed 
on the same cell line, depending on the length of exposure 
and the peptide concentration. For example, short exposure 
to PACAP increases cell proliferation, while long exposure 
inhibits it in a prostate cancer cell line (Farini et al. 2003). 
Nanomolar concentration of PACAP shows no effect on cell 
survival in case of a human retinoblastoma cell line, but 
increasing concentrations decrease cell survival (Wojcieszak 
and Zawilska 2014). As PACAP/VIP receptor family may 
have strong effects in tumour genesis, these receptors are 
frequently expressed in the most common human tumours, 
like prostate, breast, pancreatic ductal carcinoma, small cell 
lung cancer, colon adenocarcinoma, stomach, liver, urinary 
bladder, meningioma and lymphomas. The receptor type is 
predominantly VPAC1 in these cases. Leiomyomas express 
VPAC2 receptors, whereas endometrium carcinoma, para-
ganglioma, or the pheochromocytoma mainly express PAC1 
receptors (Reubi et al. 2000). Previous examinations proved 
that VIP/PACAP-receptor expression is present in only 65% 
of pancreatic ductal carcinomas, and VPAC1 and VPAC2 
receptors were found in pancreatic tumour samples (Moody 
et al. 2016). This type of receptor overexpression (Hes-
senius et al. 2000) urged the clinical use of radiolabelled 
VIP-analogues in various cancer types, including pancreas 
adenocarcinoma, VIPoma, and somatostatin analogues on 
neuroendocrine tumours (Moody et al. 2016; Raderer et al. 
1998; Tang et al. 1997). Based on the observation of Hes-
senius and co-workers (Hessenius et al. 2000), no imaging 
was seen with radiolabelled VIP-analogues in pancreatic 
cancer patients, and in vitro binding studies showed no 
overexpression of VPAC1 receptor in cases of these tumour 
types. Former studies examined PACAP expression in some 
tumours using radioimmunoassay and immunohistochem-
istry (Tamas et al. 2016). In our earlier studies, we found 
PAC1 receptor expression in the exocrine part of pancreas 
almost in all cases of normal pancreas tissue, but markedly 
low expression in the adenocarcinoma parts (Ferencz et al. 
2019), similarly to findings in lung, kidney and colon can-
cer samples, where lower PACAP tissue level was found in 
contrast to the elevated levels in prostatic cancer (Szanto 
et al. 2012; Tamas et al. 2016). An altered staining pattern 
was observed in different human testicular cancers (Naka-
mura et al. 2014) and in human thyroid papillary carcinoma 
(Bardosi et al. 2016).
In this study we found a weak PACAP expression in the 
normal exocrine pancreas, with very strong immunolabelling 
in the islets. Insulinoma samples showed markedly weaker 
staining compared to normal controls. Although our study 
involved a small number of patients, and it is not clear at this 
point what the consequences of the reduction of PACAP and 
PAC1 receptor expression are, these findings suggest a pos-
sible involvement of this system in tumour growth.
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